Literature DB >> 19896087

Defining the intensity of conditioning regimens: working definitions.

Andrea Bacigalupo1, Karen Ballen, Doug Rizzo, Sergio Giralt, Hillard Lazarus, Vincent Ho, Jane Apperley, Shimon Slavin, Marcelo Pasquini, Brenda M Sandmaier, John Barrett, Didier Blaise, Robert Lowski, Mary Horowitz.   

Abstract

Defining conditioning regimen intensity has become a critical issue for the hemopoietic stem cell transplant (HSCT) community. In the present report we propose to define conditioning regimens in 3 categories: (1) myeloablative (MA) conditioning, (2) reduced-intensity conditioning (RIC), and (3) nonmyeloablative (NMA) conditioning. Assignment to these categories is based on the duration of cytopenia and on the requirement for stem cell (SC) support: MA regimens cause irreversible cytopenia and SC support is mandatory. NMA regimens cause minimal cytopenia, and can be given also without SC support. RIC regimens do not fit criteria for MA or NMA regimens: they cause cytopenia of variable duration, and should be given with stem cell support, although cytopenia may not be irreversible. This report also assigns commonly used regimens to one of these categories, based upon the agents, dose, or combinations. Standardized classification of conditioning regimen intensities will allow comparison across studies and interpretation of study results.

Entities:  

Mesh:

Year:  2009        PMID: 19896087      PMCID: PMC2861656          DOI: 10.1016/j.bbmt.2009.07.004

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  48 in total

Review 1.  Radiation damage and repair phenomena.

Authors:  B W Fox; L G Lajtha
Journal:  Br Med Bull       Date:  1973-01       Impact factor: 4.291

2.  Marrow transplantation for thalassemia after treatment with busulfan and cyclophosphamide.

Authors:  G Lucarelli; P Polchi; T Izzi; M Manna; C Delfini; M Galimberti; A Porcellini; L Moretti; A Manna; G Sparaventi
Journal:  Ann N Y Acad Sci       Date:  1985       Impact factor: 5.691

3.  Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen.

Authors:  P J Tutschka; E A Copelan; J P Klein
Journal:  Blood       Date:  1987-11       Impact factor: 22.113

4.  One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation.

Authors:  E D Thomas; C D Buckner; M Banaji; R A Clift; A Fefer; N Flournoy; B W Goodell; R O Hickman; K G Lerner; P E Neiman; G E Sale; J E Sanders; J Singer; M Stevens; R Storb; P L Weiden
Journal:  Blood       Date:  1977-04       Impact factor: 22.113

5.  Reversal of clinical features of Hurler's disease and biochemical improvement after treatment by bone-marrow transplantation.

Authors:  J R Hobbs; K Hugh-Jones; A J Barrett; N Byrom; D Chambers; K Henry; D C James; C F Lucas; T R Rogers; P F Benson; L R Tansley; A D Patrick; J Mossman; E P Young
Journal:  Lancet       Date:  1981-10-03       Impact factor: 79.321

6.  Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities.

Authors:  Mohamed L Sorror; Michael B Maris; Barry Storer; Brenda M Sandmaier; Razvan Diaconescu; Christopher Flowers; David G Maloney; Rainer Storb
Journal:  Blood       Date:  2004-04-27       Impact factor: 22.113

7.  Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation.

Authors:  Andrea Bacigalupo; Maria Pia Sormani; Teresa Lamparelli; Francesca Gualandi; Domenico Occhini; Stefania Bregante; Anna Maria Raiola; Carmen di Grazia; Alida Dominietto; Elisabetta Tedone; Giovanna Piaggio; Marina Podesta; Barbara Bruno; Rosi Oneto; Anna Lombardi; Francesco Frassoni; Davide Rolla; Gianandrea Rollandi; Claudio Viscoli; Carlo Ferro; Lucia Garbarino; Maria Teresa Van Lint
Journal:  Haematologica       Date:  2004-10       Impact factor: 9.941

8.  Third EBMT/AMGEN Workshop on reduced-intensity conditioning allogeneic haemopoietic stem cell transplants (RIC-HSCT), and panel consensus.

Authors:  A Bacigalupo
Journal:  Bone Marrow Transplant       Date:  2004-04       Impact factor: 5.483

9.  Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research.

Authors:  Sergio Giralt; Karen Ballen; Douglas Rizzo; Andreas Bacigalupo; Mary Horowitz; Marcelo Pasquini; Brenda Sandmaier
Journal:  Biol Blood Marrow Transplant       Date:  2009-03       Impact factor: 5.742

10.  Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide.

Authors:  G W Santos; P J Tutschka; R Brookmeyer; R Saral; W E Beschorner; W B Bias; H G Braine; W H Burns; G J Elfenbein; H Kaizer
Journal:  N Engl J Med       Date:  1983-12-01       Impact factor: 91.245

View more
  475 in total

1.  Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era.

Authors:  Erica Warlick; Kwang Woo Ahn; Tanya L Pedersen; Andrew Artz; Marcos de Lima; Michael Pulsipher; Gorgun Akpek; Mahmoud Aljurf; Jean-Yves Cahn; Mitchell Cairo; Yi-Bin Chen; Brenda Cooper; Abhinav Deol; Sergio Giralt; Vikas Gupta; H Jean Khoury; Holbrook Kohrt; Hillard M Lazarus; Ian Lewis; Richard Olsson; Joseph Pidala; Bipin N Savani; Matthew Seftel; Gerard Socié; Martin Tallman; Celaettin Ustun; Ravi Vij; Lars Vindeløv; Daniel Weisdorf
Journal:  Blood       Date:  2012-03-09       Impact factor: 22.113

2.  Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplant.

Authors:  Esperanza B Papadopoulos; Miguel-Angel Perales; Jenna D Goldberg; Joanne F Chou; Steven Horwitz; Julie Teruya-Feldstein; Juliet N Barker; Farid Boulad; Hugo Castro-Malaspina; Sergio Giralt; Ann A Jakubowski; Guenther Koehne; Marcel R M van den Brink; James W Young; Zhigang Zhang
Journal:  Leuk Lymphoma       Date:  2012-01-31

Review 3.  Current status of allogeneic transplantation for aggressive non-Hodgkin lymphoma.

Authors:  Koen van Besien
Journal:  Curr Opin Oncol       Date:  2011-11       Impact factor: 3.645

Review 4.  Who is fit for allogeneic transplantation?

Authors:  H Joachim Deeg; Brenda M Sandmaier
Journal:  Blood       Date:  2010-08-11       Impact factor: 22.113

5.  Outcomes after related and unrelated umbilical cord blood transplantation for hereditary bone marrow failure syndromes other than Fanconi anemia.

Authors:  Renata Bizzetto; Carmen Bonfim; Vanderson Rocha; Gérard Socié; Franco Locatelli; Kawah Chan; Oscar Ramirez; Joel Stein; Samir Nabhan; Eliana Miranda; Jakob Passweg; Carmino Antonio de Souza; Eliane Gluckman
Journal:  Haematologica       Date:  2010-11-11       Impact factor: 9.941

6.  Dendritic Cell Recovery Impacts Outcomes after Umbilical Cord Blood and Sibling Donor Transplantation for Hematologic Malignancies.

Authors:  Waseem Touma; Claudio G Brunstein; Qing Cao; Jeffrey S Miller; Julie Curtsinger; Michael R Verneris; Veronika Bachanova
Journal:  Biol Blood Marrow Transplant       Date:  2017-07-17       Impact factor: 5.742

7.  Does total body irradiation conditioning improve outcomes of myeloablative human leukocyte antigen-identical sibling transplantations for chronic lymphocytic leukemia?

Authors:  Mitchell Sabloff; Ronald M Sobecks; Kwang Woo Ahn; Xiaochun Zhu; Marcos de Lima; Jennifer R Brown; Yoshihiro Inamoto; H Kent Holland; Mahmoud D Aljurf; Mary J Laughlin; Rammurti T Kamble; Jack W Hsu; Baldeep M Wirk; Matthew Seftel; Ian D Lewis; Mukta Arora; Edwin P Alyea; Matt E Kalaycio; Jorge Cortes; Richard T Maziarz; Robert Peter Gale; Wael Saber
Journal:  Biol Blood Marrow Transplant       Date:  2013-12-07       Impact factor: 5.742

8.  Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma.

Authors:  Mehdi Hamadani; Wael Saber; Kwang Woo Ahn; Jeanette Carreras; Mitchell S Cairo; Timothy S Fenske; Robert Peter Gale; John Gibson; Gregory A Hale; Parameswaran N Hari; Jack W Hsu; David J Inwards; Rammurti T Kamble; Anderas Klein; Dipnarine Maharaj; David I Marks; David A Rizzieri; Bipin N Savani; Harry C Schouten; Edmund K Waller; Baldeep Wirk; Ginna G Laport; Silvia Montoto; David G Maloney; Hillard M Lazarus
Journal:  Biol Blood Marrow Transplant       Date:  2013-02-01       Impact factor: 5.742

9.  Bloodstream Infection Due to Vancomycin-resistant Enterococcus Is Associated With Increased Mortality After Hematopoietic Cell Transplantation for Acute Leukemia and Myelodysplastic Syndrome: A Multicenter, Retrospective Cohort Study.

Authors:  Genovefa A Papanicolaou; Celalettin Ustun; Jo-Anne H Young; Min Chen; Soyoung Kim; Kwang Woo Ahn; Krishna Komanduri; Caroline Lindemans; Jeffery J Auletta; Marcie L Riches
Journal:  Clin Infect Dis       Date:  2019-10-30       Impact factor: 9.079

10.  Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens.

Authors:  Menachem Bitan; Wensheng He; Mei-Jie Zhang; Hisham Abdel-Azim; Mouhab Fakhreddine Ayas; Bella Bielorai; Paul A Carpenter; Mitchell S Cairo; Miguel Angel Diaz; John T Horan; Sonata Jodele; Carrie L Kitko; Kirk R Schultz; Morris Kletzel; Kimberly A Kasow; Leslie E Lehmann; Parinda A Mehta; Nirali Shah; Michael A Pulsipher; Tim Prestidge; Adriana Seber; Shalini Shenoy; Ann E Woolfrey; Lolie C Yu; Stella M Davies
Journal:  Blood       Date:  2014-01-16       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.